Current Review of Leptomeningeal Amyloidosis Associated With Transthyretin Mutations

被引:12
|
作者
Qin, Qi [1 ,4 ]
Wei, Cuibai [1 ]
Piao, YueShan [2 ]
Lian, Fang [2 ]
Wu, Hao [3 ]
Zhou, Aihong [1 ]
Wang, Fen [1 ]
Zuo, Xiumei [1 ]
Han, Yue [1 ]
Lyu, Jihui [3 ]
Guo, Dongmei [1 ]
Jia, Jianping [1 ,5 ,6 ,7 ]
机构
[1] Capital Med Univ, Dept Neurol, Innovat Ctr Neurol Disorders, Xuanwu Hosp, 45 Changchun St, Beijing 100053, Peoples R China
[2] Capital Med Univ, Xuanwu Hosp, Dept Pathol, Beijing, Peoples R China
[3] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China
[4] Beijing Geriatr Hosp, Ctr Cognit Disorders, Beijing, Peoples R China
[5] Beijing Inst Brain Disorders, Ctr Alzheimers Dis, Beijing, Peoples R China
[6] Beijing Key Lab Geriatr Cognit Disorders, Beijing, Peoples R China
[7] Neurodegenerat Lab Minist Educ Peoples Republ, Beijing, Peoples R China
基金
国家重点研发计划;
关键词
leptomeningeal amyloidosis; transthyretin; leptomeningeal enhancement; TTR mutations; FAMILIAL OCULOLEPTOMENINGEAL AMYLOIDOSIS; LIVER-TRANSPLANTATION; VARIANT; POLYNEUROPATHY; DIFLUNISAL; DIAGNOSIS; THERAPY; RARE; TAFAMIDIS; EFFICACY;
D O I
10.1097/NRL.0000000000000337
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Leptomeningeal amyloidosis (LA) represents a rare subtype of familial transthyretin (TTR) amyloidosis, characterized by deposition of amyloid in cranial and spinal leptomeninges. Of >120 TTR mutations identified, few have been associated with LA. Case Report: A 27-year-old male presented with a 2-year history of progressive symptoms including cognitive decline and right-sided weakness and numbness. Cerebrospinal fluid (CSF) analyses demonstrated high protein level. Gadolinium-enhanced magnetic resonance imaging (MRI) revealed extensive leptomeningeal enhancement over the surface of the brain and spinal cord. Pathologic analyses revealed a TTR mutation c.113A>G (p.D38G). Review Summary: Fifteen mutations and genotype-phenotype correlation of 72 LA patients have been summarized to provide an overview of LA associated with transthyretin mutations. The mean age of clinical onset was 44.9 years and the neurological symptoms primarily included cognitive impairment, headache, ataxia seizures and hearing, visual loss. CSF analysis showed elevated high CSF protein level and MRI revealed extensive leptomeningeal enhancement. Conclusion: Clinicians should be aware of this rare form of familial transthyretin amyloidosis as well as its typical MRI enhancement and high CSF protein. The important role of biopsy, genetic testing and the potential early diagnosis value of contrast MRI were suggested. Early recognition of these characteristics is important to provide misdiagnosis and shorten the time before correct diagnosis. These findings expand the phenotypic spectrum of TTR gene and have implications for the diagnosis, treatment, and systematic study of LA.
引用
收藏
页码:189 / 195
页数:7
相关论文
共 50 条
  • [1] A new transthyretin mutation associated with leptomeningeal amyloidosis
    Liepnieks, J. J.
    Dickson, D. W.
    Benson, M. D.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2011, 18 : 160 - 162
  • [2] Disease-Modifying Treatments for Transthyretin Amyloidosis
    Tushak, Zackary J.
    Cox, Stephen Zach
    Cei, Laura F.
    Gwathmey, Kelly G.
    Shah, Keyur B.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 78 (05) : e641 - e647
  • [3] Advances in the treatment of hereditary transthyretin amyloidosis: A review
    Gertz, Morie A.
    Mauermann, Michelle L.
    Grogan, Martha
    Coelho, Teresa
    BRAIN AND BEHAVIOR, 2019, 9 (09):
  • [4] Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future
    Obici, Laura
    Mussinelli, Roberta
    NEUROTHERAPEUTICS, 2021, 18 (04) : 2286 - 2302
  • [5] A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis
    Patil, Monali B.
    Ghode, Piyush
    Joshi, Prashant
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2024, 24 (06) : 571 - 587
  • [6] Oculoleptomeningeal Amyloidosis associated with transthyretin Leu12Pro in an African patient
    McColgan, P.
    Viegas, S.
    Gandhi, S.
    Bull, K.
    Tudor, R.
    Sheikh, F.
    Pinney, J.
    Fontana, M.
    Rowczenio, D.
    Gillmore, J. D.
    Gilbertson, J. A.
    Whelan, C. J.
    Shah, S.
    Jaunmuktane, Z.
    Holton, J. L.
    Schott, J. M.
    Werring, D. J.
    Hawkins, P. N.
    Reilly, M. M.
    JOURNAL OF NEUROLOGY, 2015, 262 (01) : 228 - 234
  • [7] Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy
    Poli, Loris
    Labella, Beatrice
    Cotti Piccinelli, Stefano
    Caria, Filomena
    Risi, Barbara
    Damioli, Simona
    Padovani, Alessandro
    Filosto, Massimiliano
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [8] Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy
    Dardiotis, Efthimios
    Kyriakides, Theodoros
    CURRENT NEUROPHARMACOLOGY, 2023, 21 (03) : 471 - 481
  • [9] Leptomeningeal Disease Secondary to Thr60Ala Transthyretin Amyloidosis: Case Report and Review of the Literature
    Carberry, Nathan
    Yu, Sun
    Fayerman, Raisy N.
    Dugue, Rachelle
    Miller, Michael
    Tanji, Kurenai
    Goyal, Tarini
    Canoll, Peter
    Brannagan, Thomas H., III
    NEUROHOSPITALIST, 2023, 13 (01) : 90 - 95
  • [10] Hereditary transthyretin amyloidosis overview
    Manganelli, Fiore
    Fabrizi, Gian Maria
    Luigetti, Marco
    Mandich, Paola
    Mazzeo, Anna
    Pareyson, Davide
    NEUROLOGICAL SCIENCES, 2022, 43 (Suppl 2) : 595 - 604